ワクチン市場の評価：タイプ・投与経路・適応疾患・年齢層・エンドユーザー・地域別の機会および予測 (2017～2031年)

世界のワクチンの市場規模は、2023年の1,413億米ドルから、2024年から2031年の予測期間中は3.05%のCAGRで推移し、2031年には1,796億9,000万米ドルの規模に成長すると予測されています。

世界のワクチン市場は、癌ワクチン研究への資金投入の増加、ワクチン接種キャンペーンに対する政府の支援イニシアティブ、DTaPワクチンの需要の増加、結合型ワクチンの使用の増加、患者支援・教育イニシアティブの増加などによって形成されています。

癌ワクチン研究への資金投入の増加

世界のワクチン市場の拡大は、癌ワクチン研究に対する資金調達の増加に大きく依存しています。技術革新を促進し、癌ワクチンの開発を早める政府のプログラムには、助成金、補助金、税制優遇措置などがあります。こうした資金援助により、科学者たちは重要な臨床試験を実施し、綿密な研究を行い、癌と闘うために特別に設計された新しいワクチン接種技術を研究することができます。この資金援助は、ワクチンが厳格な安全性要件を満たし、市場の信頼を得ることを保証するもので、ワクチンの商業化の成功への扉を開きます。

ワクチン接種キャンペーンに対する政府の取り組み

世界各国の政府は、ワクチン接種政策やプログラムを用いて世界のワクチン市場に大きく貢献しています。ワクチン接種キャンペーンは、大勢の人々や子どもたちにワクチンを迅速に投与する手段です。国のニーズや目標に応じて、国レベルまたは準国家レベルで、単一の抗原に対して、あるいは組み合わに対して実施されます。このような活動のスポンサーとなることで、ワクチンへの公平かつ平等なアクセスを確保すると同時に、ワクチンの重要性と信頼性に関する国民の知識を高めることができます。この戦略により、ワクチン接種の受け入れが促進され、予防接種率が向上し、地域社会の健康状態が改善されます。さらに政府は、ワクチンに関する俗説や一般的な不安を払拭し、地域社会の信頼を醸成することを目的とした教育的イニシアチブに資金を提供することも多くあります。

DTaPワクチンの需要拡大

世界のワクチン市場は、DTaP (ジフテリア、破傷風、百日咳) ワクチン接種に対する需要の高まりによっても拡大しています。この需要拡大の主な理由は、百日咳、破傷風、ジフテリアを含む疾病の発生率上昇に対処する必要性です。出生率の高さと百日咳ワクチン接種の受け入れ拡大が、DTaPワクチン市場の主な促進要因となっています。DTaP成分を含む混合ワクチンの発売も市場の成長に寄与しています。このようなニーズの高まりを満たすため、政府や製薬会社はR&Dへの投資を進めており、これが世界のワクチン市場の革新と成長に拍車をかけています。

当レポートでは、世界のワクチンの市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界のワクチン市場の展望

• 市場規模・予測
• タイプ別
  • 弱毒化生ワクチン
  • 不活化ワクチン
  • サブユニットワクチン
  • トキソイドワクチン
  • ウイルスベクターワクチン
  • mRNAワクチン
• 投与経路別
  • 筋肉内
  • 皮下
  • 経口
  • その他
• 疾患別
  • 季節性インフルエンザワクチン
  • BCGワクチン
  • DTaPワクチン
  • 帯状疱疹ワクチン
  • 肺炎球菌結合型ワクチン
  • ヒトパピローマウイルスワクチン
  • その他
• 年齢層別
  • 小児
  • 成人
• エンドユーザー別
  • 病院薬局
  • 小売薬局
  • 政府サプライヤー
  • その他
• 地域別
  • 北米
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ
• 企業別の市場シェア

第5章 世界のワクチン市場の展望：地域別

• 北米
• 欧州
• 南米
• アジア太平洋
• 中東・アフリカ

第6章 市場マッピング

• タイプ別
• 投与経路別
• 適応疾患別
• 年齢層
• エンドユーザー別
• 地域別

第7章 マクロ環境と産業構造

• 需給分析
• 輸出入分析
• バリューチェーン分析
• PESTEL分析
• ポーターのファイブフォース分析

第8章 市場力学

• 成長促進要因
• 成長阻害要因 (課題・抑制要因)

第9章 規制の枠組みとイノベーション

• 臨床試験
• 特許情勢
• 規制当局の承認
• イノベーション/新興技術

第10章 主要企業の情勢

• 市場リーダー上位5社の競合マトリックス
• 市場リーダー上位5社の市場収益分析
• M&A・ジョイントベンチャー (該当する場合)
• SWOT分析 (主要企業)
• 特許分析 (該当する場合)

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

• Pfizer Inc
• BioNTech SE ADR
• Sinovac Biotech Ltd
• Moderna Inc
• Merck & Co Inc
• GSK plc
• Sanofi SA
• Chongqing Zhifei Biological Products Co Ltd
• AstraZeneca plc
• Johnson & Johnson

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1.Global Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 2.Global Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 3.Global Vaccine Market Share (%), By Type, 2017-2031F
• Figure 4.Global Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 5.Global Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 6.Global Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 7.Global Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 8.Global Vaccine Market Share (%), By Region, 2017-2031F
• Figure 9.North America Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 10.North America Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 11.North America Vaccine Market Share (%), By Type, 2017-2031F
• Figure 12.North America Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 13.North America Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 14.North America Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 15.North America Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 16.North America Vaccine Market Share (%), By Country, 2017-2031F
• Figure 17.United States Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 18.United States Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 19.United States Vaccine Market Share (%), By Type, 2017-2031F
• Figure 20.United States Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 21.United States Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 22.United States Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 23.United States Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 24.Canada Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 25.Canada Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 26.Canada Vaccine Market Share (%), By Type, 2017-2031F
• Figure 27.Canada Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 28.Canada Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 29.Canada Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 30.Canada Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 31.Mexico Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 32.Mexico Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 33.Mexico Vaccine Market Share (%), By Type, 2017-2031F
• Figure 34.Mexico Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 35.Mexico Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 36.Mexico Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 37.Mexico Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 38.Europe Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 39.Europe Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 40.Europe Vaccine Market Share (%), By Type, 2017-2031F
• Figure 41.Europe Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 42.Europe Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 43.Europe Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 44.Europe Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 45.Europe Vaccine Market Share (%), By Country, 2017-2031F
• Figure 46.Germany Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 47.Germany Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 48.Germany Vaccine Market Share (%), By Type, 2017-2031F
• Figure 49.Germany Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 50.Germany Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 51.Germany Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 52.Germany Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 53.France Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 54.France Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 55.France Vaccine Market Share (%), By Type, 2017-2031F
• Figure 56.France Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 57.France Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 58.France Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 59.France Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 60.Italy Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 61.Italy Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 62.Italy Vaccine Market Share (%), By Type, 2017-2031F
• Figure 63.Italy Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 64.Italy Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 65.Italy Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 66.Italy Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 67.United Kingdom Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 68.United Kingdom Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 69.United Kingdom Vaccine Market Share (%), By Type, 2017-2031F
• Figure 70.United Kingdom Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 71.United Kingdom Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 72.United Kingdom Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 73.United Kingdom Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 74.Russia Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 75.Russia Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 76.Russia Vaccine Market Share (%), By Type, 2017-2031F
• Figure 77.Russia Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 78.Russia Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 79.Russia Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 80.Russia Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 81.Netherlands Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 82.Netherlands Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 83.Netherlands Vaccine Market Share (%), By Type, 2017-2031F
• Figure 84.Netherlands Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 85.Netherlands Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 86.Netherlands Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 87.Netherlands Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 88.Spain Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 89.Spain Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 90.Spain Vaccine Market Share (%), By Type, 2017-2031F
• Figure 91.Spain Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 92.Spain Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 93.Spain Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 94.Spain Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 95.Turkey Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 96.Turkey Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 97.Turkey Vaccine Market Share (%), By Type, 2017-2031F
• Figure 98.Turkey Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 99.Turkey Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 100.Turkey Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 101.Turkey Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 102.Poland Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 103.Poland Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 104.Poland Vaccine Market Share (%), By Type, 2017-2031F
• Figure 105.Poland Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 106.Poland Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 107.Poland Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 108.Poland Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 109.South America Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 110.South America Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 111.South America Vaccine Market Share (%), By Type, 2017-2031F
• Figure 112.South America Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 113.South America Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 114.South America Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 115.South America Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 116.South America Vaccine Market Share (%), By Country, 2017-2031F
• Figure 117.Brazil Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 118.Brazil Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 119.Brazil Vaccine Market Share (%), By Type, 2017-2031F
• Figure 120.Brazil Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 121.Brazil Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 122.Brazil Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 123.Brazil Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 124.Argentina Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 125.Argentina Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 126.Argentina Vaccine Market Share (%), By Type, 2017-2031F
• Figure 127.Argentina Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 128.Argentina Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 129.Argentina Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 130.Argentina Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 131.Asia-Pacific Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 132.Asia-Pacific Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 133.Asia-Pacific Vaccine Market Share (%), By Type, 2017-2031F
• Figure 134.Asia-Pacific Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 135.Asia-Pacific Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 136.Asia-Pacific Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 137.Asia- Pacific Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 138.Asia-Pacific Vaccine Market Share (%), By Country, 2017-2031F
• Figure 139.India Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 140.India Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 141.India Vaccine Market Share (%), By Type, 2017-2031F
• Figure 142.India Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 143.India Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 144.India Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 145.India Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 146.China Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 147.China Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 148.China Vaccine Market Share (%), By Type, 2017-2031F
• Figure 149.China Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 150.China Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 151.China Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 152.China Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 153.Japan Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 154.Japan Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 155.Japan Vaccine Market Share (%), By Type, 2017-2031F
• Figure 156.Japan Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 157.Japan Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 158.Japan Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 159.Japan Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 160.Australia Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 161.Australia Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 162.Australia Vaccine Market Share (%), By Type, 2017-2031F
• Figure 163.Australia Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 164.Australia Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 165.Australia Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 166.Australia Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 167.Vietnam Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 168.Vietnam Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 169.Vietnam Vaccine Market Share (%), By Type, 2017-2031F
• Figure 170.Vietnam Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 171.Vietnam Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 172.Vietnam Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 173.Vietnam Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 174.South Korea Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 175.South Korea Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 176.South Korea Vaccine Market Share (%), By Type, 2017-2031F
• Figure 177.South Korea Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 178.South Korea Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 179.South Korea Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 180.South Korea Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 181.Indonesia Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 182.Indonesia Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 183.Indonesia Vaccine Market Share (%), By Type, 2017-2031F
• Figure 184.Indonesia Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 185.Indonesia Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 186.Indonesia Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 187.Indonesia Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 188.Philippines Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 189.Philippines Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 190.Philippines Vaccine Market Share (%), By Type, 2017-2031F
• Figure 191.Philippines Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 192.Philippines Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 193.Philippines Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 194.Philippines Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 195.Middle East & Africa Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 196.Middle East & Africa Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 197.Middle East & Africa Vaccine Market Share (%), By Type, 2017-2031F
• Figure 198.Middle East & Africa Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 199.Middle East & Africa Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 200.Middle East & Africa Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 201.Middle East & Africa Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 202.Middle East & Africa Vaccine Market Share (%), By Country, 2017-2031F
• Figure 203.Saudi Arabia Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 204.Saudi Arabia Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 205.Saudi Arabia Vaccine Market Share (%), By Type, 2017-2031F
• Figure 206.Saudi Arabia Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 207.Saudi Arabia Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 208.Saudi Arabia Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 209.Saudi Arabia Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 210.UAE Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 211.UAE Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 212.UAE Vaccine Market Share (%), By Type, 2017-2031F
• Figure 213.UAE Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 214.UAE Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 215.UAE Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 216.UAE Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 217.South Africa Vaccine Market, By Value, In USD Billion, 2017-2031F
• Figure 218.South Africa Vaccine Market, By Volume, In Billion Units, 2017-2031F
• Figure 219.South Africa Vaccine Market Share (%), By Type, 2017-2031F
• Figure 220.South Africa Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 221.South Africa Vaccine Market Share (%), By Disease Indication, 2017-2031F
• Figure 222.South Africa Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 223.South Africa Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 224.By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 225.By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 226.By Disease Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 227.By Age Group Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 228.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 229.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

The global vaccine market is projected to witness a CAGR of 3.05% during the forecast period 2024-2031F, growing from USD 141.3 billion in 2023 to USD 179.69 billion in 2031F. The global vaccine market is shaped by increasing funding for cancer vaccine research, supportive government initiatives for vaccination campaigns, increased demand for DTaP vaccines, growing use of conjugate vaccines, and an increase in initiatives to support and educate patients.

The development of vaccinations against different types of malignancies has been made possible by increased funding in research, which has had a significant impact on the global vaccine market. The possibility of using immunological therapies to prevent or treat cancers increases with advances in scientific understanding. A surge in the demand for vaccinations against diphtheria, tetanus, and pertussis in the global vaccine market suggests that parents are becoming more conscious of diseases that can be prevented and are eager to shield their kids from potentially fatal conditions like whooping cough.

The initiatives taken by the governments are one of the major reasons for the substantial growth of the global vaccine market. Governments worldwide are actively promoting vaccination programs as part of their public health strategies. By supporting these efforts with resources and policy changes, governments aim to improve accessibility and coverage rates for essential vaccinations. The capacity of conjugate vaccines to offer enduring defense against bacterial infections, such as Streptococcus pneumoniae, Neisseria meningitidis serogroup C, and Haemophilus influenzae type b (Hib), has led to their increased popularity in the global vaccine market. Moreover, their rapid adoption around the world is largely due to their efficacy and safety profile.

Building trust between healthcare practitioners and patients is greatly aided by initiatives to educate and empower patients about the advantages and hazards of vaccinations. These kinds of programs also assist in clearing up misconceptions about vaccinations, which improves general adherence to advised schedules, leading to growth in the global vaccine market.

Pfizer India and Apollo Hospital jointly opened a Centre of Excellence (CoE) for adult immunization in Hyderabad in May 2023. Apollo Hospital aimed to safeguard patients from vaccine-preventable diseases (VPDs) and increase adult vaccination adoption through the establishment of an end-to-end ecosystem within the hospital.

Increased Funding for Cancer Vaccine Research

The expansion of the global vaccine market is largely dependent on increased financing for cancer vaccine research. Government programs that promote innovation and hasten the development of cancer vaccines include grants, subsidies, and tax breaks. This funding allows scientists to undertake critical clinical trials, carry out in-depth investigations, and investigate novel vaccination technologies that are specifically designed to fight cancer. This financing opens the door for the successful commercialization of vaccines by guaranteeing that they meet strict safety requirements and acquire the confidence of the market. This eventually improves public health outcomes and advances medical research in the battle against cancer.

For example, in June 2023, Pancreatic Cancer North America (PCNA) and Stand Up to Cancer (SU2C) announced PCNA's contribution of USD 1.5 million to SU2C to support pancreatic cancer vaccine development. The trial's vaccination was specifically designed to identify the cancer cells found in each participant's pancreatic cancer tumor and boost the immune system's ability to combat the malignancy.

Government Initiatives for Vaccination Campaigns

Governments across the globe are driving substantial contributions to the global vaccine market using vaccination policies and programs. Vaccination campaigns are a means of promptly administering vaccines to a large group of people or children. Depending on the needs and goals of the nation, they can be carried out at the national or sub-national level, for a single antigen, or in combination. Through their sponsorship of these activities, they ensure fair and equal access to vaccines, while increasing public knowledge of their importance and dependability. This strategy encourages greater vaccination acceptance, which raises immunization rates and improves community health outcomes. Furthermore, governments frequently provide funding for educational initiatives aimed at dispelling myths and common worries about vaccines, fostering community trust.

The Human Papillomavirus (HPV) vaccination campaign was initiated by the Government of Bangladesh in October 2023, with assistance from UNICEF, the Vaccine Alliance (Gavi), and the World Health Organisation (WHO). By preventing cervical cancer, a disease that kills thousands of women in Bangladesh each year, this program seeks to safeguard the health and future of millions of girls throughout the nation.

Increased Demand for DTaP Vaccines

The global vaccine market is expanding due to the rising demand for DTaP (Diphtheria, Tetanus, and Acellular Pertussis) vaccinations. The primary reason for this growth in demand is the need to address the rising incidence of diseases, including pertussis, tetanus, and diphtheria. The high birth rate and the growing acceptance of the pertussis vaccination are the main drivers of the DTaP vaccine market. The launch of combination vaccines with DTaP components also contribute to the growth of the market. To fulfill this growing need, governments and pharmaceutical companies are making investments in R&D, which is spurring innovation and growth in the global vaccine market.

In December 2023, India, Panacea Biotec, the biotechnology company, introduced EasyFourPol, a fully liquid pentavalent vaccination based on wP-IPV. Children are protected against five lethal diseases by the wP-IPV pentavalent vaccine: invasive infections caused by Haemophilus influenza type B, pertussis, polio, tetanus, and diphtheria. Furthermore, the company declared that Panacea Biotec Germany GmbH, its step-down, wholly owned subsidiary, had registered Valganciclovir 50 mg/mL powder for oral solution in Germany.

Growing Use of Conjugate Vaccines

The global vaccination market is expanding due to the increasing usage of conjugate vaccines. The use of conjugate vaccines has increased because of their success in lowering the incidence of diseases and promoting strong immunity, particularly in susceptible groups such as young children and newborns. Due to their proven ability to effectively target a variety of diseases, these vaccines are essential components of global immunization programs. Researchers have been able to build conjugate vaccines with increased features, broadening their usefulness across numerous diseases, primarily made possible through advancements in biotechnology and vaccine development.

The World Health Organization (WHO), in February 2024, granted prequalification (PQ) approval to SK Bioscience, a South Korean biotech and vaccine business dedicated to advancing human health from prevention to cure, for their typhoid conjugate vaccine (TCV), SKYTyphoid. The company has already gotten two influenza vaccinations and a varicella vaccine. This is its fourth WHO PQ.

North America Dominating the Market

The global vaccine market is dominated by North America. This dominance is primarily due to the region's robust immunization and health welfare programs, solid government policies, and sophisticated research skills. North America's position as a major player in the global vaccination industry is further cemented by the existence of respectable manufacturers and sufficient financing regulations. Furthermore, the region's emphasis on raising the coverage of immunizations through partnerships and government initiatives supports its continued growth and market leadership. Increased knowledge and understanding of vaccines in these nations motivate people to seek prompt medical care, which fuels demand for vaccine treatments and aids in the growth of the global vaccine market

Valneva SE, a specialty vaccine manufacturer, declared in November 2023 that IXCHIQ, a single-dose, live-attenuated vaccine developed by Valneva, has been approved by the FDA for the prevention of chikungunya virus (CHIKV)-related illness in people 18 years of age and older who are at an increased risk of exposure.

Future Market Scenario (2024 - 2031F)

By utilizing the skills and extensive knowledge of innovation leaders, major firms in the global vaccination market are cooperating to share next-generation vaccine platforms, helping them get past hurdles to competition.

To find new development opportunities, companies in the worldwide vaccine market are working on needle-free delivery and investigating emerging disease indications like CMV and glioblastoma, an aggressive form of cancer.

Nucleic acid-based vaccines have shown considerable promise in treating HIV and cancer. As a result, the global vaccine market is expected to rise at a promising rate.

Asthma, diabetes, and respiratory syncytial virus (RSV) infections are among the new disease categories that companies in the global vaccine market are investigating, and which have not yet been the subject of vaccine research.

Key Players Landscape and Outlook

To maximize benefits and increase their market share, major players in the global vaccine market are collaborating more and more. Through these partnerships, businesses may pool their knowledge, assets, and technological know-how to expedite vaccine research, expand manufacturing capabilities, and effectively tackle global health concerns. Companies can efficiently bring breakthrough vaccines to market by collaborating with other businesses to obtain complementary talents, share knowledge, and pool resources. This cooperative strategy ensures a more thorough response to public health demands, promotes research improvements, and improves the vaccination market, in addition to encouraging innovation.

A strategic alliance was announced on February 26, 2024, by Takeda and Biological E. Limited (BE), a well-known pharmaceutical and vaccine company in India, to expedite access to QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials (MDVs). To boost national immunization programs, governments in endemic countries will eventually be able to purchase these doses by 2030 at the latest.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Vaccine Market Outlook, 2017-2031F

• 4.1.Market Size & Forecast
  • 4.1.1.By Value
  • 4.1.2.By Volume
• 4.2.By Type
  • 4.2.1.Live-attenuated Vaccine
  • 4.2.2.Inactivated Vaccine
  • 4.2.3.Subunit Vaccine
  • 4.2.4.Toxoid Vaccine
  • 4.2.5.Viral Vector Vaccine
  • 4.2.6.mRNA Vaccine
• 4.3.By Route of Administration
  • 4.3.1.Intramuscular
  • 4.3.2.Subcutaneous
  • 4.3.3.Oral
  • 4.3.4.Others
• 4.4.By Disease Indication
  • 4.4.1.Seasonal Influenza Vaccine
  • 4.4.2.BCG Vaccine
  • 4.4.3.DTaP Vaccine
  • 4.4.4.Shingles Vaccine
  • 4.4.5.Pneumococcal Conjugate Vaccine
  • 4.4.6.Human Papillomavirus Vaccine
  • 4.4.7.Others
• 4.5.By Age Group
  • 4.5.1.Pediatric
  • 4.5.2.Adult
• 4.6.By End-user
  • 4.6.1.Hospital Pharmacies
  • 4.6.2.Retail Pharmacies
  • 4.6.3.Government Suppliers
  • 4.6.4.Others
• 4.7.By Region
  • 4.7.1.North America
  • 4.7.2.Europe
  • 4.7.3.Asia-Pacific
  • 4.7.4.South America
  • 4.7.5.Middle East and Africa
• 4.8.By Company Market Share (%), 2023

5.Global Vaccine Market Outlook, By Region, 2017-2031F

• 5.1.North America*
  • 5.1.1.Market Size & Forecast
    • 5.1.1.1.By Value
    • 5.1.1.2.By Volume
  • 5.1.2.By Type
    • 5.1.2.1.Live-attenuated Vaccine
    • 5.1.2.2.Inactivated Vaccine
    • 5.1.2.3.Subunit Vaccine
    • 5.1.2.4.Toxoid Vaccine
    • 5.1.2.5.Viral Vector Vaccine
    • 5.1.2.6.mRNA Vaccine
  • 5.1.3.By Route of Administration
    • 5.1.3.1.Intramuscular
    • 5.1.3.2.Subcutaneous
    • 5.1.3.3.Oral
    • 5.1.3.4.Others
  • 5.1.4.By Disease Indication
    • 5.1.4.1.Seasonal Influenza Vaccine
    • 5.1.4.2.BCG Vaccine
    • 5.1.4.3.DTaP Vaccine
    • 5.1.4.4.Shingles Vaccine
    • 5.1.4.5.Pneumococcal Conjugate Vaccine
    • 5.1.4.6.Human Papillomavirus Vaccine
    • 5.1.4.7.Others
  • 5.1.5. By Age Group
    • 5.1.5.1.Pediatric
    • 5.1.5.2.Adult
  • 5.1.6.By End-user
    • 5.1.6.1.Hospital Pharmacies
    • 5.1.6.2.Retail Pharmacies
    • 5.1.6.3.Government Suppliers
    • 5.1.6.4.Others
  • 5.1.7.United States*
    • 5.1.7.1.Market Size & Forecast
    • 5.1.7.1.1.By Value
    • 5.1.7.1.2.By Volume
    • 5.1.7.2.By Type
    • 5.1.7.2.1.Live-attenuated Vaccine
    • 5.1.7.2.2.Inactivated Vaccine
    • 5.1.7.2.3.Subunit Vaccine
    • 5.1.7.2.4.Toxoid Vaccine
    • 5.1.7.2.5.Viral Vector Vaccine
    • 5.1.7.2.6.mRNA Vaccine
    • 5.1.7.3.By Route of Administration
    • 5.1.7.3.1.Intramuscular
    • 5.1.7.3.2.Subcutaneous
    • 5.1.7.3.3.Oral
    • 5.1.7.3.4.Others
    • 5.1.7.4.By Disease Indication
    • 5.1.7.4.1.Seasonal Influenza Vaccine
    • 5.1.7.4.2.BCG Vaccine
    • 5.1.7.4.3.DTaP Vaccine
    • 5.1.7.4.4.Shingles Vaccine
    • 5.1.7.4.5.Pneumococcal Conjugate Vaccine
    • 5.1.7.4.6.Human Papillomavirus Vaccine
    • 5.1.7.4.7.Others
    • 5.1.7.5.By Age Group
    • 5.1.7.5.1.Pediatric
    • 5.1.7.5.2.Adult
    • 5.1.7.6.By End-user
    • 5.1.7.6.1.Hospital Pharmacies
    • 5.1.7.6.2.Retail Pharmacies
    • 5.1.7.6.3.Online Pharmacies
    • 5.1.7.6.4.Others
  • 5.1.8.Canada
  • 5.1.9.Mexico

All segments will be provided for all regions and countries covered

• 5.2.Europe
  • 5.2.1.Germany
  • 5.2.2.France
  • 5.2.3.Italy
  • 5.2.4.United Kingdom
  • 5.2.5.Russia
  • 5.2.6.Netherlands
  • 5.2.7.Spain
  • 5.2.8.Turkey
  • 5.2.9.Poland
• 5.3.Asia-Pacific
  • 5.3.1.India
  • 5.3.2.China
  • 5.3.3.Japan
  • 5.3.4.Australia
  • 5.3.5.Vietnam
  • 5.3.6.South Korea
  • 5.3.7.Indonesia
  • 5.3.8.Philippines
• 5.4.South America
  • 5.4.1.Brazil
  • 5.4.2.Argentina
• 5.5.Middle East & Africa
  • 5.5.1.Saudi Arabia
  • 5.5.2.UAE
  • 5.5.3.South Africa

6.Market Mapping, 2023

• 6.1.By Type
• 6.2.By Route of Administration
• 6.3.By Disease Indication
• 6.4.By Age Group
• 6.5.By End-user
• 6.6.By Region

7.Macro Environment and Industry Structure

• 7.1.Demand Supply Analysis
• 7.2.Import Export Analysis
• 7.3.Value Chain Analysis
• 7.4.PESTEL Analysis
  • 7.4.1.Political Factors
  • 7.4.2.Economic System
  • 7.4.3.Social Implications
  • 7.4.4.Technological Advancements
  • 7.4.5.Environmental Impacts
  • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5.Porter's Five Forces Analysis
  • 7.5.1.Supplier Power
  • 7.5.2.Buyer Power
  • 7.5.3.Substitution Threat
  • 7.5.4.Threat from New Entrant
  • 7.5.5.Competitive Rivalry

8.Market Dynamics

• 8.1.Growth Drivers
• 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

• 9.1.Clinical Trials
• 9.2.Patent Landscape
• 9.3.Regulatory Approvals
• 9.4.Innovations/Emerging Technologies

10.Key Players Landscape

• 10.1.Competition Matrix of Top Five Market Leaders
• 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4.SWOT Analysis (For Five Market Players)
• 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

• 13.1.Pfizer Inc
  • 13.1.1.Company Details
  • 13.1.2.Key Management Personnel
  • 13.1.3.Products & Services
  • 13.1.4.Financials (As reported)
  • 13.1.5.Key Market Focus & Geographical Presence
  • 13.1.6.Recent Developments
• 13.2.BioNTech SE ADR
• 13.3.Sinovac Biotech Ltd
• 13.4.Moderna Inc
• 13.5.Merck & Co Inc
• 13.6.GSK plc
• 13.7.Sanofi SA
• 13.8.Chongqing Zhifei Biological Products Co Ltd
• 13.9.AstraZeneca plc
• 13.10.Johnson & Johnson

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer